LENVIMA

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Feb 13, 2015

   11 yr 6 mo ago

2. Exclusivity ends · ODE-196

   Orphan-drug exclusivity (7 years)

   Aug 15, 2025

   10 mo ago

3. Patent 7253286 expires

   Listed drug substance patent expiration.

   Oct 24, 2025

   8 mo ago

4. Exclusivity ends · PED

   Pediatric exclusivity (adds 6 months)

   Feb 15, 2026

   4 mo ago

5. Patent 7253286*PED expires

   Listed listed patent expiration.

   Apr 24, 2026

   2 mo ago

6. Today

7. Patent 7612208 expires

   Listed drug substance patent expiration.

   Sep 19, 2026

   in 3 mo

8. Patent 7612208*PED expires

   Listed listed patent expiration.

   Mar 19, 2027

   in 9 mo

9. Exclusivity ends · M-14

   New use / labeling-change exclusivity (3 years)

   Apr 03, 2027

   in 10 mo

10. Patent 9006256 expires

    Listed method-of-use patent (U-1695) expiration.

    Jul 27, 2027

    in 1 yr 1 mo

11. Exclusivity ends · PED

    Pediatric exclusivity (adds 6 months)

    Oct 03, 2027

    in 1 yr 4 mo

12. Patent 9006256*PED expires

    Listed listed patent expiration.

    Jan 27, 2028

    in 1 yr 8 mo

13. Patent 12508313 expires

    Listed drug product patent expiration.

    Oct 04, 2030

    in 4 yr 4 mo

14. Patent 12508313*PED expires

    Listed listed patent expiration.

    Apr 04, 2031

    in 4 yr 10 mo

15. Patent 10259791 expires

    Listed drug substance patent expiration.

    Aug 26, 2035

    in 9 yr 4 mo

16. Patent 10407393 expires

    Listed drug substance patent expiration.

    Aug 26, 2035

    in 9 yr 4 mo

17. Patent 11186547 expires

    Listed drug substance patent expiration.

    Aug 26, 2035

    in 9 yr 4 mo

18. Patent 11090386 expires

    Listed method-of-use patent (U-3519) expiration.

    Feb 23, 2036

    in 9 yr 10 mo

19. Patent 10259791*PED expires

    Listed listed patent expiration.

    Feb 26, 2036

    in 9 yr 10 mo

20. Patent 10407393*PED expires

    Listed listed patent expiration.

    Feb 26, 2036

    in 9 yr 10 mo

21. Patent 11186547*PED expires

    Listed listed patent expiration.

    Feb 26, 2036

    in 9 yr 10 mo

22. Patent 12083112 expires

    Listed method-of-use patent (U-3996) expiration.

    Mar 03, 2036

    in 9 yr 10 mo

23. Patent 12083112 expires

    Listed method-of-use patent (U-3997) expiration.

    Mar 03, 2036

    in 9 yr 10 mo

24. Patent 11090386*PED expires

    Listed listed patent expiration.

    Aug 23, 2036

    in 10 yr 4 mo

25. Patent 12083112*PED expires

    Listed listed patent expiration.

    Sep 03, 2036

    in 10 yr 4 mo

26. Patent 12226409 expires

    Listed method-of-use patent (U-4146) expiration.

    May 15, 2038

    in 12 yr 1 mo

27. Patent 12226409*PED expires

    Listed listed patent expiration.

    Nov 15, 2038

    in 12 yr 7 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (4)

• ODE-196Orphan-drug exclusivity (7 years)

  Aug 15, 2025

  10 mo ago

• PEDPediatric exclusivity (adds 6 months)

  Feb 15, 2026

  4 mo ago

• M-14New use / labeling-change exclusivity (3 years)

  Apr 03, 2027

  in 10 mo

• PEDPediatric exclusivity (adds 6 months)

  Oct 03, 2027

  in 1 yr 4 mo

Listed patents (21)